| Literature DB >> 34592195 |
Rifaquat Rahman1, Steffen Ventz2, Jon McDunn3, Bill Louv3, Irmarie Reyes-Rivera4, Mei-Yin C Polley5, Fahar Merchant6, Lauren E Abrey7, Joshua E Allen8, Laura K Aguilar9, Estuardo Aguilar-Cordova9, David Arons10, Kirk Tanner10, Stephen Bagley11, Mustafa Khasraw12, Timothy Cloughesy13, Patrick Y Wen14, Brian M Alexander15, Lorenzo Trippa2.
Abstract
Integration of external control data, with patient-level information, in clinical trials has the potential to accelerate the development of new treatments in neuro-oncology by contextualising single-arm studies and improving decision making (eg, early stopping decisions). Based on a series of presentations at the 2020 Clinical Trials Think Tank hosted by the Society of Neuro-Oncology, we provide an overview on the use of external control data representative of the standard of care in the design and analysis of clinical trials. High-quality patient-level records, rigorous methods, and validation analyses are necessary to effectively leverage external data. We review study designs, statistical methods, risks, and potential distortions in using external data from completed trials and real-world data, as well as data sources, data sharing models, ongoing work, and applications in glioblastoma.Entities:
Mesh:
Substances:
Year: 2021 PMID: 34592195 PMCID: PMC8893120 DOI: 10.1016/S1470-2045(21)00488-5
Source DB: PubMed Journal: Lancet Oncol ISSN: 1470-2045 Impact factor: 41.316